Nkarta Sees Unusually High Options Volume (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) saw unusually large options trading activity on Tuesday. Investors bought 4,525 put options on the stock. This represents an increase of 2,359% compared to the average daily volume of 184 put options.

Analysts Set New Price Targets

Several research analysts have commented on NKTX shares. HC Wainwright decreased their target price on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a report on Monday, November 11th. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Mizuho decreased their target price on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a report on Thursday, November 21st. Raymond James upgraded shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price for the company in a report on Wednesday, August 14th. Finally, Rodman & Renshaw assumed coverage on shares of Nkarta in a report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $15.00.

Nkarta Stock Up 1.2 %

NASDAQ NKTX opened at $2.52 on Thursday. The stock has a market capitalization of $177.83 million, a PE ratio of -1.32 and a beta of 0.82. The company has a 50 day moving average price of $3.27 and a two-hundred day moving average price of $4.91. Nkarta has a 12-month low of $2.35 and a 12-month high of $16.24.

Hedge Funds Weigh In On Nkarta

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Nkarta by 26.0% during the first quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock worth $21,255,000 after acquiring an additional 405,753 shares during the period. AQR Capital Management LLC acquired a new stake in Nkarta during the second quarter worth $938,000. Federated Hermes Inc. boosted its stake in Nkarta by 28,478.7% during the second quarter. Federated Hermes Inc. now owns 135,749 shares of the company’s stock worth $802,000 after buying an additional 135,274 shares in the last quarter. Wasatch Advisors LP boosted its stake in Nkarta by 31.7% during the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after buying an additional 442,125 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Nkarta during the second quarter worth $1,489,000. Institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.